Search

Your search keyword '"Weckesser, Matthias"' showing total 493 results
Start Over Author "Weckesser, Matthias"
493 results on '"Weckesser, Matthias"'

1. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

Author

Seifert, Robert, Kersting, David, Rischpler, Christoph, Sandach, Patrick, Ferdinandus, Justin, Fendler, Wolfgang P., Rahbar, Kambiz, Weckesser, Matthias, Umutlu, Lale, Hanoun, Christine, Hüttmann, Andreas, Reinhardt, Hans Christian, von Tresckow, Bastian, Herrmann, Ken, Dührsen, Ulrich, and Schäfers, Michael

Published
2022
Full Text
View/download PDF

13. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

Author

Hüttmann, Andreas, Rekowski, Jan, Müller, Stefan P., Hertenstein, Bernd, Franzius, Christiane, Mesters, Rolf, Weckesser, Matthias, Kroschinsky, Frank, Kotzerke, Jörg, Ganser, Arnold, Bengel, Frank M., La Rosée, Paul, Freesmeyer, Martin, Höffkes, Heinz-Gert, Hertel, Andreas, Behringer, Dirk, Prange-Krex, Gabriele, Griesshammer, Martin, Holzinger, Jens, Wilop, Stefan, Krohn, Thomas, Raghavachar, Aruna, Maschmeyer, Georg, Brink, Ingo, Schroers, Roland, Gaska, Tobias, Bernhard, Helga, Giagounidis, Aristoteles, Schütte, Jochen, Dienst, Ariane, Hautzel, Hubertus, Naumann, Ralph, Klein, Alfred, Hahn, Dennis, Pöpperl, Gabriele, Grube, Matthias, Marienhagen, Jörg, Schwarzer, Andreas, Kurch, Lars, Höhler, Thomas, Steiniger, Heike, Nückel, Holger, Südhoff, Thomas, Römer, Wolfgang, Brinkmann, Marcus, Ose, Claudia, Alashkar, Ferras, Schmitz, Christine, Dürig, Jan, Hoelzer, Dieter, Jöckel, Karl-Heinz, Klapper, Wolfram, and Dührsen, Ulrich

Published
2019
Full Text
View/download PDF

19. Supplementary Materials from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

Author

Agelopoulos, Konstantin, primary, Richter, Günther H.S., primary, Schmidt, Eva, primary, Dirksen, Uta, primary, von Heyking, Kristina, primary, Moser, Benjamin, primary, Klein, Hans-Ulrich, primary, Kontny, Udo, primary, Dugas, Martin, primary, Poos, Kathrin, primary, Korsching, Eberhard, primary, Buch, Thorsten, primary, Weckesser, Matthias, primary, Schulze, Isabell, primary, Besoke, Regina, primary, Witten, Anika, primary, Stoll, Monika, primary, Köhler, Gabriele, primary, Hartmann, Wolfgang, primary, Wardelmann, Eva, primary, Rossig, Claudia, primary, Baumhoer, Daniel, primary, Jürgens, Heribert, primary, Burdach, Stefan, primary, Berdel, Wolfgang E., primary, and Müller-Tidow, Carsten, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures S1-6 from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

Author

Agelopoulos, Konstantin, primary, Richter, Günther H.S., primary, Schmidt, Eva, primary, Dirksen, Uta, primary, von Heyking, Kristina, primary, Moser, Benjamin, primary, Klein, Hans-Ulrich, primary, Kontny, Udo, primary, Dugas, Martin, primary, Poos, Kathrin, primary, Korsching, Eberhard, primary, Buch, Thorsten, primary, Weckesser, Matthias, primary, Schulze, Isabell, primary, Besoke, Regina, primary, Witten, Anika, primary, Stoll, Monika, primary, Köhler, Gabriele, primary, Hartmann, Wolfgang, primary, Wardelmann, Eva, primary, Rossig, Claudia, primary, Baumhoer, Daniel, primary, Jürgens, Heribert, primary, Burdach, Stefan, primary, Berdel, Wolfgang E., primary, and Müller-Tidow, Carsten, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables S1-6 from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

Author

Agelopoulos, Konstantin, primary, Richter, Günther H.S., primary, Schmidt, Eva, primary, Dirksen, Uta, primary, von Heyking, Kristina, primary, Moser, Benjamin, primary, Klein, Hans-Ulrich, primary, Kontny, Udo, primary, Dugas, Martin, primary, Poos, Kathrin, primary, Korsching, Eberhard, primary, Buch, Thorsten, primary, Weckesser, Matthias, primary, Schulze, Isabell, primary, Besoke, Regina, primary, Witten, Anika, primary, Stoll, Monika, primary, Köhler, Gabriele, primary, Hartmann, Wolfgang, primary, Wardelmann, Eva, primary, Rossig, Claudia, primary, Baumhoer, Daniel, primary, Jürgens, Heribert, primary, Burdach, Stefan, primary, Berdel, Wolfgang E., primary, and Müller-Tidow, Carsten, primary

Published
2023
Full Text
View/download PDF

22. 18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)

Author

Roll, Wolfgang, Schindler, Philipp, Masthoff, Max, Strotmann, Rebecca, Albring, Jörn Christian, Reicherts, Christian, Weckesser, Matthias, Noto, Benjamin, Stelljes, Matthias, Schäfers, Michael, Evers, Georg Heribert, and Universitäts- und Landesbibliothek Münster

Subjects
GvHD, Inflammation, FDG, 610 Medicine and health, Research, PET-MRI, Medicine and health, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ddc:610, RC254-282
Abstract

Background: Graft versus host disease (GvHD) is a frequent complication of allogeneic stem cell transplantation (alloSCT), significantly increasing mortality. Previous imaging studies focused on the assessment of intestinal GvHD with contrast-enhanced MRI/CT or 18F-FDG-PET imaging alone. The objective of this retrospective study was to elucidate the diagnostic value of a combined 18F-FDG-PET-MRI protocol in patients with acute intestinal GvHD. Methods: Between 2/2015 and 8/2019, 21 patients with acute intestinal GvHD underwent 18F-FDG-PET-MRI. PET, MRI and PET-MRI datasets were independently reviewed. Readers assessed the number of affected segments of the lower gastrointestinal tract and the reliability of the diagnosis on a 5-point Likert scale and quantitative PET (SUVmax, SUVpeak, metabolic volume (MV)) and MRI parameter (wall thickness), were correlated to clinical staging of acute intestinal GvHD. Results: The detection rate for acute intestinal GvHD was 56.8% for PET, 61.4% for MRI and 100% for PET-MRI. PET-MRI (median Likert-scale value: 5; range: 4–5) offers a significantly higher reliability of the diagnosis compared to PET (median: 4; range: 2–5; p = 0.01) and MRI alone (median: 4; range: 3–5; p = 0.03). The number of affected segments in PET-MRI (rs = 0.677; p < 0.001) and the MV (rs = 0.703; p < 0.001) correlated significantly with the clinical stage. SUVmax (rs = 0.345; p = 0.14), SUVpeak (rs = 0.276; p = 0.24) and wall thickening (rs = 0.174; p = 0.17) did not show a significant correlation to clinical stage. Conclusion: 18F-FDG-PET-MRI allows for highly reliable assessment of acute intestinal GvHD and adds information indicating clinical severity., Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022.

Published
2023

38. Translational Imaging of the Fibroblast Activation Protein (FAP) Using the New Ligand [68Ga]Ga-OncoFAP-DOTAGA

Author

Backhaus, Philipp, primary, Gierse, Florian, additional, Burg, M.C., additional, Büther, Florian, additional, Asmus, Inga, additional, Dorten, Paulina Marie, additional, Cufe, Juela, additional, Roll, Wolfgang, additional, Neri, Dario, additional, Cazzamalli, Samuele, additional, Millul, Jacopo, additional, Mock, Jacqueline, additional, Galbiati, Andrea, additional, Zana, Aureliano, additional, Schäfers, Klaus P., additional, Hermann, Sven, additional, Weckesser, Matthias, additional, Tio, Joke, additional, Wagner, Stefan, additional, Breyholz, Hans-Jörg, additional, and Schäfers, Michael, additional

Published
2021
Full Text
View/download PDF

39. Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [ 18 F]F-PSMA 1007 PET.

Author

Relt, Elisabeth, Roll, Wolfgang, Claesener, Michael, Bögemann, Martin, Weckesser, Matthias, and Rahbar, Kambiz

Subjects
TIME, RADIOISOTOPES, POSITRON emission tomography, PROSTATE-specific antigen, PROSTATE tumors
Abstract

Simple Summary: The total number of PSMA-PET-CT examinations for the staging of prostate cancer patients has increased in recent years, following its superior imaging properties. Fluorinated PSMA ligands can be produced in larger amounts, facilitating higher patient throughput compared to the initially developed gallium labelled PSMA-tracers; allowing PET in only a few patients per synthesis. This results in a longer time after, typically early morning, radiochemical synthesis (TaS) of [18]F-PSMA when the PSMA-PET scan is performed. Moreover, novel fluorinated-PSMA compounds are injected around two hours before PET-CT and the time after injection (TaI) might show significant deviation. [18F]-PSMA PET offers improved detection rates in the proximity of the urinary tract; however, it has the disadvantage of more unspecific uptake, e.g., in the skeleton. This article focusses on the question whether TaS or TaI have an influence on uptake patterns in malignant lesions and healthy tissue. PET imaging using PSMA ligands is increasingly used for staging in prostate cancer patients in different clinical indications. Unlike [68Ga]Ga-labeled PSMA ligands, fluorinated compounds can be produced in large amounts; thus, they can be used for a higher number of patients. One concern is that in patients studied a long time after synthesis (TaS) or time after injection (TaI), the specific activity may decline; thus, the signal may be lower in these patients. In this study, we investigated a potential effect of TaS and TaI on image quality. In total, 134 consecutive patients were included in this retrospective analysis on the effect of TaS and TaI on uptake in prostate cancer lesions. All the patients underwent [18F]F-PSMA-1007 PET-CT from 99 min up to 549 min after tracer quality control. TaS and TaI were compared to the quantitative tumoral uptake parameters SUVmax and SUVpeak. In a second exploratory part of the analysis, TaS and TaI were correlated to a physiological tracer uptake in different organs. TaS and TaI did not affect the SUVmax and SUVpeak in tumor lesions in [18F]F-PSMA-1007 PET. The physiological uptake in salivary glands, lacrimal glands and the ganglia, spleen and urine was not significantly correlated to TaS or TaI; in contrast to the mean liver uptake, showing a weak, but significant correlation to TaS. The [18F]F-PSMA-1007 uptake in prostate cancer lesions is not significantly dependent on the TaS and TaI. These results are extremely reassuring when performing [18F]F-PSMA-1007 PET a considerable time after synthesis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Evaluation of⁶⁸ga-psma-11 pet-mri in patients with advanced prostate cancer receiving¹⁷⁷lu-psma-617 therapy : A radiomics analysis

Author

Roll, Wolfgang, Schindler, Philipp, Masthoff, Max, Seifert, Robert, Schlack, Katrin, Bögemann, Martin, Stegger, Lars, Weckesser, Matthias, and Rahbar, Kambiz

Subjects
Medizin, urologic and male genital diseases
Abstract

¹⁷⁷Lutetium PSMA-617 (Lu-PSMA) therapy in patients with metastatic castration resistant prostate cancer (mCRPC) has gained visibility through the ongoing phase III trial. The data on prediction of therapy outcome and survival out of pretherapeutic imaging parameters is still sparse. In this study, the predictive and prognostic value of radiomic features from⁶⁸Ga-PSMA-11 PET-MRI are analyzed. In total, 21 patients with mCRPC underwent⁶⁸Ga-PSMA-11 PET-MRI before Lu-PSMA therapy. The PET-positive tumor volume was defined and transferred to whole-body T2-, T1-and contrast-enhanced T1-weighted MRI-sequences. The radiomic features from PET and MRI sequences were extracted by using a freely available software package. For selecting features that allow differentiation of biochemical response (PSA decrease > 50%), a stepwise dimension reduction was performed. Logistic regression models were fitted, and selected features were tested for their prognostic value (overall survival) in all patients. Eight patients achieved biochemical response after Lu-PSMA therapy. Ten independent radiomic features differentiated well between responders and non-responders. The logistic regression model, including the feature interquartile range from T2-weighted images, revealed the highest accuracy (AUC = 0.83) for the prediction of biochemical response after Lu-PSMA therapy. Within the final model, patients with a biochemical response (p = 0.003) and higher T2 interquartile range values in pre-therapeutic imaging (p = 0.038) survived significantly longer. This proof-of-concept study provides first evidence on a potential predictive and prognostic value of radiomic analysis of pretherapeutic⁶⁸Ga-PSMA-11 PET-MRI before Lu-PSMA therapy. CA extern

Published
2021

43. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Author

Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weber, Manuel, Herrmann, Ken, Spanke, Maximilian, Fendler, Wolfgang, Hadaschik, Boris, Kleesiek, Jens, Schäfers, Michael, Weckesser, Matthias, Boegemann, Martin, and Rahbar, Kambiz

Subjects
Medizin, urologic and male genital diseases
Abstract

Introduction: [¹⁷⁷Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. Methods: A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmₑₐn), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmₑₐn₎ were quantified for each patient. Log2 transformation was used for regressions. Results: Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. Conclusion: PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.

Published
2021

45. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Author

Kobe, Carsten, Dietlein, Markus, Franklin, Jeremy, Markova, Jana, Lohri, Andreas, Amthauer, Holger, Klutmann, Susanne, Knapp, Wolfram H., Zijlstra, Josee M., Bockisch, Andreas, Weckesser, Matthias, Lorenz, Reinhard, Schreckenberger, Mathias, Bares, Roland, Eich, Hans T., Mueller, Rolf-Peter, Fuchs, Michael, Borchmann, Peter, Schicha, Harald, Diehl, Volker, and Engert, Andreas

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results